Maxim drug combo shows promise
Adjust font size:
Manufacturing News, Source : TheManufacturer.com
Published : 13 May 2004 14:46
Maxim Pharmaceuticals claims a combination of its Ceplene drug plus interleukin-2 prevented acute myeloid leukemia relapse in an end-stage clinical trial.
Maxim Pharmaceuticals claims a combination of its Ceplene drug plus interleukin-2 prevented acute myeloid leukemia relapse in an end-stage clinical trial. After the announcement, Maxim’s stock climbed by more than a dollar in Wednesday afternoon trading to a high of $10.45 per share.
Acute myeloid leukemia (AML) is the most common form of leukemia in adults. AML patients are usually treated with chemotherapy, but the majority often suffer a relapse. After a relapse, the outlook is often grim, with few long-term survivors.
In Maxim's Phase 3 trial, 320 AML patients in complete remission in Europe, North America, Israel, New Zealand, and Australia were randomly selected to receive Ceplene plus interleukin-2 or no treatment at all for at least three years. Patients treated with Ceplene and IL-2 had a statistically significant improvement of leukemia-free survival compared to patients who received no treatment at all. Additional details are slated to be presented at upcoming meetings.
Comments on this story
click here to add a comment
You must be registered & logged in to add comments
already have an account and just want to login?
Related Content
Guest Editorial: Checklist - Seven Recommendations for Improved Profits
by Abbott A. Imberman, PhD, Professor of...
more…
FKI LOGISTEX OPENS NORTH AMERICAN TECHNOLOGY & EDUCATION CENTER (TEC)
(St. Louis, Missouri, USA: July 10, 2007) FKI...
more…
Guess selects the tradecard platformand SourceView suite to optimize global trade
NEW YORK, July 10, 2007 – TradeCard Inc., the...
more…
Kimberly-Clark Professional Crosses Final Touchless Frontier With Introduction of First Electronic Bath Tissue Dispenser
ROSWELL, Ga. (July 9, 2007) – Kimberly-Clark...
more…
Boeing Celebrates the Premiere of the 787 Dreamliner
EVERETT, Wash., July 08, 2007 -- Today, Boeing...
more…
no comments yet...